**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event\* Drug interaction

In a case report, a 74-year-old man and a 63-year-old woman were described, who exhibited increased ruxolitinib serum concentration along with purpuric lesions, decreased platelet count, soft-tissue infection, herpes labialis, low haemoglobin, decreased haematocrit value or erythrodermic rash following concomitant administration of off-label lopinavir/ritonavir and ruxolitinib for coronavirus disease 2019 (COVID-19). Additionally, both the patients received off-label treatment with dexamethasone, enoxaparin-sodium, hydroxychloroquine or tocilizumab for COVID-19 \[*not all routes stated; duration of treatment to reactions onsets and outcomes not stated*\].

Case 1: The 74-year-old man, who presented to the emergency room was diagnosed with SARS coronavirus-2 (SARS-CoV-2) infection via RT-PCR at hospital admission. Thereafter, he was started on non-invasive ventilation and received enoxaparin-sodium \[enoxaparin\] 6000IU, lopinavir/ritonavir \[200mg/50mg\] 2 tablets twice daily, dexamethasone 20mg and hydroxychloroquine 400 mg/day as an off-label treatment for COVID-19 infection. Due to persistent deterioration, after 5 weeks of admission, he received off-label two subcutaneous tocilizumab 162mg injections per 2 cycles a week and exhibited subsequent clinical and radiological improvement. A week later, despite clinical stability his laboratory parameters increased again. Thus, to prevent a relapse, he received ruxolitinib (compassionate use) 5mg 2 tablets/day for 2 days, and 4 tablets/day for 3 days, then precociously tapered. However, ruxolitinib was discontinued as he developed purpuric skin lesions on the dorsal and upper limbs along with decreased platelet count in 5 days and a deep tissue infection of the left arm along with rapid drop in haematocrit values. Therefore, he was treated with unspecified steroids and unspecified antibiotics. Development of the side effects were attributed to drug interaction between lopinavir/ritonavir and ruxolitinib, as ruxolitinib serum concentration may have increased due to

ritonavir.

Case 2: The 63-year-old woman was diagnosed with SARS-CoV-2 infection and admitted to hospital. She had a history of hypothyroidism and was receiving treatment with levothyroxine sodium. Thereafter, she was started on enoxaparin-sodium 6000IU, lopinavir/ritonavir \[200mg/50mg\] 2 tablets twice daily, hydroxychloroquine 200mg as an off-label treatment for COVID-19 infection. She required prolonged low-volume oxygen therapy. On the 12 day after admission, she received treatment with ruxolitinib (compassionate use) 5mg 2 tablets/day for 3 days, and then the dose was doubled. The day ruxolitinib was doubled her SARS-CoV-2 swab was negative; However, she developed herpes labialis, thus ruxolitinib was then decreased to 5 mg/day along with initiation of acyclovir therapy. But, 4 days later, haematocrits showed a progressive reduction of haemoglobin values and she developed an erythrodermic rash on her entire body surface along with rapid drop in haematocrit values. Ruxolitinib was quickly stopped and unspecified steroid therapy was administered for 5 days. Development of the side effects were attributed to drug interaction between lopinavir/ritonavir and ruxolitinib, as ruxolitinib serum concentration may have increased due to ritonavir.
